A post-hoc analysis of data from 13 clinical trials, including 6155 patients treated with OCR, revealed key insights on infection risks in patients with multiple sclerosis (PwMS). Over a median treatment period of 3.7 years, 6.8% of patients experienced serious infections (SIs), with the most common being respiratory, urinary, abdominal, gastrointestinal, and skin infections. Most cases (~90%) resolved, and treatment continued in over 80% of patients. Significant risk factors for SIs included the presence of comorbidities, high EDSS scores, and recent relapse activity, while time on OCR was not significantly associated with an increased risk of infections. The findings suggest that continuous treatment with OCR shows a manageable infection profile, and addressing modifiable risk factors may further reduce infection risks.
We would like to congratulate the entire team for this important contribution to multiple sclerosis research, and a special shout-out to our very own Prof. Ludwig Kappos and Tobias Derfuss from RC2NB for their significant contributions to this study!
Full article: https://journals.sagepub.com/doi/10.1177/17562864241277736
